Literature DB >> 9185703

Human pancreatic cancer cells (MPanc-96) recognized by autologous tumor-infiltrating lymphocytes after in vitro as well as in vivo tumor expansion.

M Peiper1, M Nagoshi, D Patel, J A Fletcher, P S Goegebuure, T J Eberlein.   

Abstract

A human tumor line designated MPanc-96 has been established from a poorly differentiated primary pancreatic adenocarcinoma. MPanc-96 has a doubling time of 27 hr and grows as a confluent monolayer in various culture media. Cytogenetic analysis of in vitro-cultured tumor cells revealed a large number of clonal chromosomal aberrations, confirming their neoplastic origin. MPanc-96 grows in SCID mice when injected s.c. Xenografts established from the tumor line had a similar histology as the primary tumor. Tumor-infiltrating lymphocytes (TILs) were isolated from the primary tumor, and cytotoxic T lymphocytes (CTLs) were generated after activation on immobilized anti-CD3 monoclonal antibody (MAb) for 48 hr, expansion in low-dose IL-2 and repeated stimulation with irradiated MPanc-96 tumor cells. The generated CTLs lysed fresh autologous tumor cells as well as in vitro and in vivo expanded tumor cells from passages 9-53, suggesting that one or more tumor-associated antigens (TAAs) are stably expressed. CTLs lysed tumor cells in an HLA-class I-restricted fashion but showed no significant cytotoxicity against autologous fibroblasts, several allogeneic pancreatic cancer cell lines or K562. Our findings may be significant for the design of an animal model for studying the mechanisms of immunotherapy in human pancreatic cancer or for the identification of TAAs in pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9185703     DOI: 10.1002/(sici)1097-0215(19970611)71:6<993::aid-ijc15>3.0.co;2-7

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Molecular imaging of Cathepsin E-positive tumors in mice using a novel protease-activatable fluorescent probe.

Authors:  Wael R Abd-Elgaliel; Zobeida Cruz-Monserrate; Craig D Logsdon; Ching-Hsuan Tung
Journal:  Mol Biosyst       Date:  2011-09-20

2.  Detection of pancreatic cancer tumours and precursor lesions by cathepsin E activity in mouse models.

Authors:  Zobeida Cruz-Monserrate; Wael R Abd-Elgaliel; Tobias Grote; Defeng Deng; Baoan Ji; Thiruvengadam Arumugam; Huamin Wang; Ching-Hsuan Tung; Craig D Logsdon
Journal:  Gut       Date:  2011-11-07       Impact factor: 23.059

3.  Intensity of the vaccine-elicited immune response determines tumor clearance.

Authors:  Ainhoa Perez-Diez; Paul J Spiess; Nicholas P Restifo; Polly Matzinger; Francesco M Marincola
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

4.  Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models.

Authors:  Thiruvengadam Arumugam; Vijaya Ramachandran; Craig D Logsdon
Journal:  J Natl Cancer Inst       Date:  2006-12-20       Impact factor: 13.506

5.  Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer.

Authors:  Murali D Bashyam; Ryan Bair; Young H Kim; Pei Wang; Tina Hernandez-Boussard; Collins A Karikari; Robert Tibshirani; Anirban Maitra; Jonathan R Pollack
Journal:  Neoplasia       Date:  2005-06       Impact factor: 5.715

6.  Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival.

Authors:  Vijaya Ramachandran; Thiruvengadam Arumugam; Huamin Wang; Craig D Logsdon
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

7.  Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer.

Authors:  Tobias Grote; Doris R Siwak; Herbert A Fritsche; Corwin Joy; Gordon B Mills; Diane Simeone; David C Whitcomb; Craig D Logsdon
Journal:  Proteomics       Date:  2008-08       Impact factor: 3.984

8.  Designing and developing S100P inhibitor 5-methyl cromolyn for pancreatic cancer therapy.

Authors:  Thiruvengadam Arumugam; Vijaya Ramachandran; Duoli Sun; Zhenghong Peng; Ashutosh Pal; David S Maxwell; William G Bornmann; Craig D Logsdon
Journal:  Mol Cancer Ther       Date:  2013-01-09       Impact factor: 6.261

9.  In vivo imaging of pancreatic tumours and liver metastases using 7 Tesla MRI in a murine orthotopic pancreatic cancer model and a liver metastases model.

Authors:  Ivo L Partecke; André Kaeding; Matthias Sendler; Nele Albers; Jens-P Kühn; Sven Speerforck; Sebastian Roese; Florian Seubert; Stephan Diedrich; Sandra Kuehn; Ulrich F Weiss; Julia Mayerle; Markus M Lerch; Stefan Hadlich; Norbert Hosten; Claus-D Heidecke; Ralf Puls; Wolfram von Bernstorff
Journal:  BMC Cancer       Date:  2011-01-28       Impact factor: 4.430

10.  The ADMR receptor mediates the effects of adrenomedullin on pancreatic cancer cells and on cells of the tumor microenvironment.

Authors:  Vijaya Ramachandran; Thiruvengadam Arumugam; Robert Langley; Rosa F Hwang; Pablo Vivas-Mejia; Anil K Sood; Gabriel Lopez-Berestein; Craig D Logsdon
Journal:  PLoS One       Date:  2009-10-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.